BRAF
BRAF
Lynch syndrome
colorectal cancer
immunohistochemistry
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
03 Jan 2024
03 Jan 2024
Historique:
revised:
20
11
2023
received:
12
07
2023
accepted:
18
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
4
1
2024
Statut:
aheadofprint
Résumé
The Lynch syndrome (LS) screening algorithm requires BRAF testing as a fundamental step to distinguish sporadic from LS-associated colorectal carcinomas (CRC). BRAF testing by immunohistochemistry (IHC) has shown variable results in the literature. Our aim was to analyse concordance between BRAF MisMatch repair (MMR) protein (hMLH1, hPMS2, hMSH2, and hMSH6) and BRAF BRAF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Histopathology published by John Wiley & Sons Ltd.
Références
Peltomäki P, Nyström M, Mecklin JP, Seppälä TT. Lynch syndrome genetics and clinical implications. Gastroenterology 2023; 164; 783-799.
Latham A, Srinivasan P, Kemel Y et al. Microsatellite instability is associated with the presence of Lynch Syndrome pan-cancer. J. Clin. Oncol. 2019; 37; 286-295.
Wang C, Zhang L, Vakiani E, Shia J. Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both? Mod. Pathol. 2022; 35; 1515-1528.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet. Med. 2009; 11; 35-41.
Stjepanovic N, Moreira L, Carneiro F et al. ESMO Guidelines Committee. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019; 30; 1558-1571.
Weiss JM, Gupta S, Burke CA et al. NCCN Guidelines® insights: genetic/familial high-risk assessment: colorectal, version 1.2021. J. Natl. Compr. Canc. Netw. 2021; 19; 1122-1132.
West NP, Gallop N, Kaye D et al. Yorkshire cancer research Bowel Cancer Improvement Programme Group. Lynch syndrome screening in colorectal cancer: results of a prospective 2-year regional programme validating the NICE diagnostics guidance pathway throughout a 5.2-million population. Histopathology 2021; 79; 690-699.
Tibiletti MG, Carnevali I, Calò V et al. Universal testing for MSI/MMR status in colorectal and endometrial cancers to identify Lynch syndrome cases: state of the art in Italy and consensus recommendations from the Italian Association for the Study of Familial Gastrointestinal Tumors (A.I.F.E.G.). Eur. J. Cancer Prev. 2022; 31; 44-49.
Loughrey MB, Waring PM, Tan A et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam. Cancer 2007; 6; 301-310.
Adar T, Rodgers LH, Shannon KM et al. Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. Cancer 2018; 124; 3145-3153.
Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71; 209-249.
Mesteri I, Bayer G, Meyer J et al. Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. Mod. Pathol. 2014; 27; 135-144.
Hang JF, Li AF, Chang SC, Liang WY. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test. Histopathology 2016; 69; 54-62.
Bledsoe JR, Kamionek M, Mino-Kenudson M. BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity. Am. J. Surg. Pathol. 2014; 38; 1418-1428.
Kuan SF, Navina S, Cressman KL, Pai RK. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization. Hum. Pathol. 2014; 45; 464-472.
Panarelli NC, Weidner AS, Yantiss RK, Chen YT. A cautionary note on the immunohistochemical detection of BRAF V600E mutations in serrated lesions of the colon. Mod. Pathol. 2015; 28; 740-741.
Estrella JS, Tetzlaff MT, Bassett RL Jr et al. Assessment of BRAF V600E status in colorectal carcinoma: tissue-specific discordances between immunohistochemistry and sequencing. Mol. Cancer Ther. 2015; 14; 2887-2895.
Adackapara CA, Sholl LM, Barletta JA, Hornick JL. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology 2013; 63; 187-193.
Lasota J, Kowalik A, Wasag B et al. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach. Am. J. Surg. Pathol. 2014; 38; 1235-1241.
Day F, Muranyi A, Singh S et al. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target. Oncol. 2015; 10; 99-109.
Rossle M, Sigg M, Ruschoff JH et al. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. Virchows Arch. 2013; 463; 623-631.
Dvorak K, Higgins A, Palting J, Cohen M, Brunhoeber P. Immunohistochemistry with anti-BRAF V600E (VE1) mouse monoclonal antibody is a sensitive method for detection of the BRAF V600E mutation in colon cancer: evaluation of 120 cases with and without KRAS mutation and literature review. Pathol. Oncol. Res. 2019; 25; 349-359.
Martinuzzi C, Pastorino L, Andreotti V et al. A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer. Endocrine 2016; 53; 672-680.
Bruno W, Martinuzzi C, Andreotti V et al. Italian Melanoma Intergroup (IMI). Heterogeneity and frequency of BRAF mutations in primary melanoma: comparison between molecular methods and immunohistochemistry. Oncotarget 2017; 8; 8069-8082.
Bragoni A, Gambella A, Pigozzi S et al. Quality control in diagnostic immunohistochemistry: integrated on-slide positive controls. Histochem. Cell Biol. 2017; 148; 569-573.
Fassan M, Scarpa A, Remo A et al. Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. Pathologica 2020; 112; 248-259.
Gambella A, Porro L, Pigozzi S, Fiocca R, Grillo F, Mastracci L. Section detachment in immunohistochemistry: causes, troubleshooting, and problem-solving. Histochem. Cell Biol. 2017; 148; 95-101.
Taieb J, Le Malicot K, Shi Q et al. Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. J. Natl. Cancer Inst. 2016; 31; djw272.
Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J. Gastrointest. Oncol. 2015; 6; 660-667.
Angerilli V, Sabella G, Centonze G et al. BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications. Crit. Rev. Oncol. Hematol. 2022; 172; 103647.
Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008; 26; 5705-5712.
Kopetz S, Grothey A, Yaeger R et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 2019; 381; 1632-1643.
Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum. Pathol. 2013; 44; 2563-2570.
Parente P, Grillo F, Vanoli A et al. The day-to-day practice of MMR and MSI assessment in colorectal adenocarcinoma: what we know and what we still need to explore. Dig. Dis. 2023; 1; 746-756.
Dvorak K, Aggeler B, Palting J, McKelvie P, Ruszkiewicz A, Waring P. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of preanalytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Pathology 2014; 46; 509-517.
Pai RK, Jayachandran P, Koong AC et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am. J. Surg. Pathol. 2012; 36; 744-752.
Grillo F, Paudice M, Gambella A et al. Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens. Histochem. Cell Biol. 2023; 160; 113-125.
Capper D, Voigt A, Bozukova G et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int. J. Cancer 2013; 133; 1624-1630.
Toon CW, Walsh MD, Chou A et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am. J. Surg. Pathol. 2013; 37; 1592-1602.
Roth RM, Hampel H, Arnold CA, Yearsley MM, Marsh WL, Frankel WL. A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial. Am. J. Clin. Pathol. 2015; 143; 336-343.
Nolan S, Arnason T, Drucker A, Huang WY. The utility of BRAFV600E mutation-specific antibody for colon cancers with microsatellite instability. Appl. Immunohistochem. Mol. Morphol. 2014; 22; e8-e13.